Balanced news tone
News Sentiment
TPST sentiment intelligence
Tempest Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
50
Balanced news tone
55 relevant articles
Price is moving more forcefully than the current news tone suggests.
82/100 classification confidence.
directly relevant articles
high-authority source matches
-10.7% over one week, -22.8% over four weeks, trend inactive, and below fair value.
Tempest plans trial of in vivo CAR-T candidate for autoimmune diseases By Investing.com
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
82/100 classification
One-week reaction
-10.7%
Price reacting lower
Trend fit
Trend inactive
-22.8% over four weeks
Fair value
-94.6%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
6
Neutral
42
Negative
7
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Investing.com South Africa
Direct company coverage
Tempest plans trial of in vivo CAR-T candidate for autoimmune diseases By Investing.com
Tempest Therapeutics announced plans to initiate a clinical trial for its lead in vivo CAR-T candidate, TPST-4003, for nervous system autoimmune diseases, including myasthenia gravis and multiple sclerosis. The trial is expected to enroll around 10 patients, with the first dosing
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jul 2026 19:10
- Source
- Investing.com South Africa
Quiver Quantitative
Direct company coverage
Tempest Therapeutics Announces Advancement of Lead In Vivo CAR-T Candidate TPST-4003 into Planned Autoimmune Disease Trial
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jul 2026 11:13
- Source
- Quiver Quantitative
GlobeNewswire
Direct company coverage
Tempest Unveils Next-Generation In Vivo CAR-T Pipeline
Tempest Therapeutics has announced its next-generation in vivo CAR-T pipeline, with the lead candidate TPST-4003 targeting nervous system autoimmune diseases like myasthenia gravis and multiple sclerosis. The company plans to initiate a clinical trial for TPST-4003 in the fourth
- Tone
- Positive 71/100
- Event
- Market update
- Published
- 15 Jul 2026 12:10
- Source
- GlobeNewswire
Stock Titan
Direct company coverage
Tempest's planned CAR-T study targets myasthenia gravis and MS
Tempest Therapeutics announced plans to advance its lead in vivo CAR-T candidate, TPST-4003, into a 10-patient investigator-initiated clinical trial targeting nervous system autoimmune diseases like myasthenia gravis and multiple sclerosis. The study, anticipated to start dosing
- Tone
- Positive 77/100
- Event
- Market update
- Published
- 15 Jul 2026 10:59
- Source
- Stock Titan
GlobeNewswire
Direct company coverage
Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026
Tempest Therapeutics announced details of its next-generation in vivo CAR-T platform, with their lead candidate TPST-4003 advancing into a clinical trial for nervous system autoimmune diseases like myasthenia gravis and multiple sclerosis. The company plans to dose the first pati
- Tone
- Positive 72/100
- Event
- Earnings
- Published
- 15 Jul 2026 10:59
- Source
- GlobeNewswire
Market source
Industry context
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
Stock Titan
Direct company coverage
Tempest Therapeutics (NASDAQ: TPST) registers 2.43M shares for resale tied to warrants
Tempest Therapeutics (NASDAQ: TPST) has registered 2,426,897 shares of its common stock for resale, comprising shares issuable upon the exercise of newly issued warrants and placement agent warrants. The company will not receive proceeds from the direct resale of these shares by
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jul 2026 20:09
- Source
- Stock Titan
Stock Titan
Direct company coverage
[EFFECT] Tempest Therapeutics, Inc. SEC Filing
This article reports on an SEC filing by Tempest Therapeutics, Inc. (TPST), specifically an "EFFECT" filing which is a Notice of Effectiveness for an S-3 Shelf Registration. The filing was accepted by the SEC on July 8, 2026, and became effective on July 7, 2026. The report also
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jul 2026 10:09
- Source
- Stock Titan
Stock Titan
Direct company coverage
Tempest Therapeutics (NASDAQ: TPST) seeks shareholder vote to amend charter
Tempest Therapeutics is seeking shareholder approval to amend its certificate of incorporation, aiming to replace existing supermajority voting requirements with majority-of-outstanding standards and permit stockholder action by written consent. The Board unanimously recommends a
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 07 Jul 2026 21:44
- Source
- Stock Titan
TradingView
Direct company coverage
Enterprise value to revenue forward of Tempest Therapeutics, Inc. – NASDAQ:TPST
The article focuses on the enterprise value to revenue forward metric for Tempest Therapeutics, Inc. (NASDAQ: TPST). It appears to be a financial data point presented within a TradingView context, potentially indicating an analysis or overview of the company's valuation. However,
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 04 Jul 2026 11:10
- Source
- TradingView
MT Newswires
Direct company coverage
Rani Therapeutics Names Nicholas Maestas CFO
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Jun 2026 12:55
- Source
- MT Newswires
TradingView
Direct company coverage
TPST Forecast — Price Target — Prediction for 2027
This article provides a forecast for Tempest Therapeutics, Inc. (TPST), including analyst price targets and future predictions. It details the company's current stock performance, market capitalization, earnings, and revenue, alongside responses to frequently asked questions abou
- Tone
- Negative 39/100
- Event
- Earnings
- Published
- 27 Jun 2026 05:09
- Source
- TradingView
Moomoo
Direct company coverage
Tempest Therapeutics Registers 2.43 Million Shares for Resale
Tempest Therapeutics has registered 2.43 million shares for resale, as detailed in a recent SEC filing. This move allows existing shareholders, likely including certain investors or employees, to sell their shares on the open market. The registration does not indicate a new issua
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 00:09
- Source
- Moomoo
GuruFocus
Direct company coverage
TPST: Selling Stockholders Plan to Offer 2.43 Million Shares
Certain stockholders of Tempest Therapeutics Inc (TPST) plan to sell 2.43 million shares of common stock. The company itself will not participate in the sale or benefit from the proceeds. TPST, a small-cap biotechnology company with a market cap of $15.99 million, has a low GF Sc
- Tone
- Negative 38/100
- Event
- Market update
- Published
- 26 Jun 2026 20:40
- Source
- GuruFocus
Stock Titan
Direct company coverage
Tempest Therapeutics (NASDAQ: TPST) registers 2.43M shares from warrants
Tempest Therapeutics (NASDAQ: TPST) has registered up to 2.43 million shares of common stock for resale by selling stockholders, stemming from new and placement agent warrants. The company will not receive proceeds from these resales, but could gain approximately $4.23 million if
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 19:40
- Source
- Stock Titan
TradingView
Direct company coverage
Price to earnings forward of Tempest Therapeutics, Inc. – NASDAQ:TPST
This page provides financial data, primarily the "Price to earnings forward" value, for Tempest Therapeutics, Inc. (NASDAQ: TPST). It indicates that the company's market is currently closed with no trades. The content is essentially a snapshot of a financial data point from Tradi
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 26 Jun 2026 02:39
- Source
- TradingView
TradingView
Direct company coverage
Price to sales forward of Tempest Therapeutics, Inc. – NASDAQ:TPST
This page displays the "Price to sales forward" metric for Tempest Therapeutics, Inc. (NASDAQ: TPST) on TradingView. The content is primarily navigation and boilerplate information from the TradingView platform, with no specific financial data or analysis for TPST provided on thi
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Jun 2026 22:10
- Source
- TradingView
TradingView
Direct company coverage
Price to sales forward of Tempest Therapeutics, Inc. – LS:A41556
This article provides the "Price to sales forward" value for Tempest Therapeutics, Inc. (A41556) on TradingView. It indicates that the market is closed and no trades have occurred for this specific period, presenting the financial data as "No trades." The brief content focuses so
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Jun 2026 20:39
- Source
- TradingView
TradingView
Direct company coverage
Tempest Therapeutics, Inc. Actuals & Estimates (NASDAQ:TPST)
This article provides an overview of Tempest Therapeutics, Inc. (NASDAQ:TPST) stock performance, financial actuals, and future estimates. It details the current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings report. The piece also
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Jun 2026 18:10
- Source
- TradingView
Intellectia AI
Direct company coverage
TPST PE Ratio & Valuation, Is TPST Overvalued
This article analyzes the valuation of Tempest Therapeutics Inc (TPST), stating that it is currently in the "Fair zone" based on its forward P/S ratio compared to its five-year average. It details various financial metrics such as P/B ratio and Free Cash Flow yield, noting signif
- Tone
- Negative 39/100
- Event
- Balance sheet
- Published
- 24 Jun 2026 12:39
- Source
- Intellectia AI
Investing.com Nigeria
Direct company coverage
Form 8K Tempest Therapeutics Inc For: 23 June By Investing.com
This article reports on the filing of a Form 8K by Tempest Therapeutics Inc. on June 23, 2026. The brief notice from Investing.com indicates this financial filing is available for public consumption. It is a standard reporting for a company, signifying a significant event worthy
- Tone
- Negative 32/100
- Event
- Market update
- Published
- 24 Jun 2026 03:41
- Source
- Investing.com Nigeria
Investing.com Nigeria
Direct company coverage
Form 4 Tempest Therapeutics Inc For: 23 June By Investing.com
The article reports on a Form 4 filing for Tempest Therapeutics Inc. on June 23, 2026, as published by Investing.com. It is a brief news item indicating a regulatory disclosure for the company. The specific details of the Form 4 filing are not included in this snippet.
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 23 Jun 2026 22:10
- Source
- Investing.com Nigeria
Stock Titan
Direct company coverage
CEO-linked entity boosts Tempest (TPST) stake with stock and new warrants
An entity linked to Tempest Therapeutics CEO, Factor Bioscience Inc., acquired 231,482 shares of common stock and warrants to purchase an additional 462,964 shares at a combined price of $2.16 per share plus a warrant. The CEO, Matthew Angel, controls Factor Bioscience and thus i
- Tone
- Positive 70/100
- Event
- Deals and strategy
- Published
- 23 Jun 2026 20:39
- Source
- Stock Titan
Simply Wall Street
Direct company coverage
Tempest Therapeutics (Nasdaq:TPST) - Stock Analysis
Tempest Therapeutics (TPST) is a clinical-stage biotechnology company focused on developing therapies for cancer, with a market capitalization of US$18.6 million. The company faces significant risks including shareholder dilution, negative earnings forecasts, low revenue, and Nas
- Tone
- Negative 29/100
- Event
- Earnings
- Published
- 23 Jun 2026 16:10
- Source
- Simply Wall Street
Stock Titan
Direct company coverage
Tempest Therapeutics (NASDAQ: TPST) holders approve warrant share issuances
Tempest Therapeutics (NASDAQ: TPST) stockholders approved two proposals at their 2026 Special Meeting, authorizing the potential issuance of common stock related to previously issued warrants. This includes shares for Series A, Series B, and Common Warrants, formalizing prior fin
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Jun 2026 11:10
- Source
- Stock Titan
Investing.com
Direct company coverage
Tempest Therapeutics shareholders approve issuance of up to 4.2 million shares
Tempest Therapeutics shareholders have approved the issuance of up to 4.2 million common shares related to outstanding warrants, following a special meeting. The biotech company, trading near its 52-week low, secured these approvals under Nasdaq Rule 5635 due to thresholds on out
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Jun 2026 10:10
- Source
- Investing.com
Minichart
Direct company coverage
Tempest Therapeutics, Inc. 8-K Filing – Special Meeting Results, Common Stock Issuance Approved, Company Details (June 2026) – Minichart
Tempest Therapeutics, Inc. announced the results of its 2026 Special Meeting, where shareholders approved the issuance of over 4 million new common shares under Nasdaq Rule 5635. These approvals for Series A and B warrants, and inducement offer warrants, enable the company to rai
- Tone
- Negative 37/100
- Event
- Earnings
- Published
- 23 Jun 2026 10:10
- Source
- Minichart
TradingKey
Direct company coverage
Tempest Therapeutics Inc (TPST) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Tempest Therapeutics Inc (TPST), outlining major individual and institutional holders. It provides a breakdown of shareholder types, institutional holdings over recent quarters, and recent shareholder activity with specific change
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 16:10
- Source
- TradingKey
TradingKey
Direct company coverage
Tempest Therapeutics Inc (TPST) Institutional Confidence
This article from TradingKey provides an overview of institutional confidence in Tempest Therapeutics Inc (TPST). It details the shares held by various institutional shareholders, including Angel (Matthew), Lotus Capital Limited, and Versant Ventures, along with changes in their
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 14:09
- Source
- TradingKey
TradingKey
Direct company coverage
Tempest Therapeutics Inc (TPST) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides historical data on dividends and stock splits for Tempest Therapeutics Inc (TPST). It states that no dividends have been distributed over the past five years and lists several merger-related stock splits with their corresponding dates and ratios. The company
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 18 Jun 2026 10:10
- Source
- TradingKey